|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2003-4-17
|
|
pubmed:abstractText |
Combretastatin A-4 disodiumphosphate (CA4P), a prodrug formulation of the natural product combretastatin A-4 (CA4), is currently in clinical investigation for the treatment of cancer. In vivo, CA4P is rapidly enzymatically converted to CA4, a potent inhibitor of tubulin polymerization (IC(50)=1-2 microM), and rapidly causes bloodflow shutdown in tumor tissues. A variety of alkyl and aryl di- and triesters of CA4P have been synthesized and evaluated as potential CA4 prodrugs and/or stable CA4P analogues.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:EdvardsenKlausK,
pubmed-author:HadimaniMallinath BMB,
pubmed-author:HuaJianyiJ,
pubmed-author:JonklaasM DevanMD,
pubmed-author:KaneRobert RRR,
pubmed-author:KesslerRaymond JRJ,
pubmed-author:OlivaresAdrianA,
pubmed-author:PinneyKevin GKG,
pubmed-author:ShengYezhouY,
pubmed-author:TanpureRajendra PRP,
pubmed-author:WeiserAimeeA,
pubmed-author:ZhangJianxingJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
5
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1505-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Synthesis, in vitro, and in vivo evaluation of phosphate ester derivatives of combretastatin A-4.
|
|
pubmed:affiliation |
Department of Chemistry & Biochemistry, Center for Drug Discovery, Baylor University, Waco, TX 76798-7348, USA.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
